Crinetics Pharmaceuticals, Inc. — Director's Dealing 2019

Jun 26, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Crinetics Pharmaceuticals, Inc. (CRNX)
CIK: 0001658247
Period of Report: 2019-06-21

Reporting Person: 5AM Ventures IV, L.P. (Former 10% holder)
Reporting Person: 5AM Co-Investors IV, L.P. (Former 10% holder)
Reporting Person: 5AM Partners IV, LLC (Former 10% holder)
Reporting Person: ROCKLAGE SCOTT M (Former 10% holder)
Reporting Person: DIEKMAN JOHN D (Former 10% holder)
Reporting Person: Schwab Andrew J. (Former 10% holder)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-06-21	Common Stock	S	240000	$22.20	Disposed	2267797	Indirect
2019-06-21	Common Stock	S	10000	$22.20	Disposed	94489	Indirect

Footnotes

F1: These securities are held by by 5AM Ventures IV, L.P. ("Ventures IV"). 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Ventures IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein.

F2: These securities are held by 5AM Co-Investors IV, L.P. ("Co-Investors IV"). Partners IV is the sole general partner of Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Co-Investors IV, and have shared voting and investment power over the shares beneficially owned by Co-Investors IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein.